A NOVEL THERAPEUTIC APPROACH TO COLORECTAL CANCER IN DIABETES: ROLE OF METFORMIN AND RAPAMYCIN

Manfredi Rizzo, Francesco Cappello, Angelo Leone, Giovanni Tomasello, Assaad Eid, Alice Gerges Geagea, Sahar Al Kattar, Céline Gracia, Liliane Massaad-Massade, Abdo Jurjus

Risultato della ricerca: Article

Abstract

The link between colorectal cancer (CRC), diabetes mellitus (DM) and inflammation is well established, and polyterapy, including rapamycin, has been adopted. This study is a novel approach that aimed at assessing the effect of a combination therapy of metformin and rapamycin on the control or prevention of CRC in diabetic animals, in presence or absence of probiotics. Fifty NOD/SCIDs male mice developed xenograft by inoculating HCT16 cells. They were equally divided into diabetics (induced by Streptozocin) and non-diabetics. Metformin was given in drinking water, whereas rapamycin was administered via intra-peritoneal injections. Probiotics were added to the double therapy two weeks before the sacrifice. Assessment was performed by clinical observation, histological analysis. Reactive oxigen species (ROS) activities and molecular analysis of Interleukin 3 and 6. Tumor Necrosis Factor alpha. AMP-activated protein Kinase and the mammalian target of rapamycin. decreases in the level of tumorigenesis resulted, to various extents, with the different treatment regimens.The combination of rapamycin and metformin had no significant result, however, after adding probiotics to the combination, there was a marked delay in tumor formation and reduction of its siza, suppression of ROS and decrease in inflammatory cytokines as well as an inhibition of phospohorylated mTOR. Existing evidence clearly supports the use of rapamycin and metformin especially in the presence of probiotics. It also highlighted the possible mechanism of action of the 2 drugs through AMPK and mTOR signaling pathways and offered preliminary data on the significant role of probiotics in the combination. Further investigation to clarify is needed.
Lingua originaleEnglish
pagine (da-a)1284-1305
Numero di pagine22
RivistaDefault journal
Volume10
Stato di pubblicazionePublished - 2019

All Science Journal Classification (ASJC) codes

  • Oncology

Cita questo

A NOVEL THERAPEUTIC APPROACH TO COLORECTAL CANCER IN DIABETES: ROLE OF METFORMIN AND RAPAMYCIN. / Rizzo, Manfredi; Cappello, Francesco; Leone, Angelo; Tomasello, Giovanni; Eid, Assaad; Geagea, Alice Gerges; Kattar, Sahar Al; Gracia, Céline; Massaad-Massade, Liliane; Jurjus, Abdo.

In: Default journal, Vol. 10, 2019, pag. 1284-1305.

Risultato della ricerca: Article

Rizzo, M, Cappello, F, Leone, A, Tomasello, G, Eid, A, Geagea, AG, Kattar, SA, Gracia, C, Massaad-Massade, L & Jurjus, A 2019, 'A NOVEL THERAPEUTIC APPROACH TO COLORECTAL CANCER IN DIABETES: ROLE OF METFORMIN AND RAPAMYCIN', Default journal, vol. 10, pagg. 1284-1305.
Rizzo, Manfredi ; Cappello, Francesco ; Leone, Angelo ; Tomasello, Giovanni ; Eid, Assaad ; Geagea, Alice Gerges ; Kattar, Sahar Al ; Gracia, Céline ; Massaad-Massade, Liliane ; Jurjus, Abdo. / A NOVEL THERAPEUTIC APPROACH TO COLORECTAL CANCER IN DIABETES: ROLE OF METFORMIN AND RAPAMYCIN. In: Default journal. 2019 ; Vol. 10. pagg. 1284-1305.
@article{77060f99c6744425bcc317caeac6263f,
title = "A NOVEL THERAPEUTIC APPROACH TO COLORECTAL CANCER IN DIABETES: ROLE OF METFORMIN AND RAPAMYCIN",
abstract = "The link between colorectal cancer (CRC), diabetes mellitus (DM) and inflammation is well established, and polyterapy, including rapamycin, has been adopted. This study is a novel approach that aimed at assessing the effect of a combination therapy of metformin and rapamycin on the control or prevention of CRC in diabetic animals, in presence or absence of probiotics. Fifty NOD/SCIDs male mice developed xenograft by inoculating HCT16 cells. They were equally divided into diabetics (induced by Streptozocin) and non-diabetics. Metformin was given in drinking water, whereas rapamycin was administered via intra-peritoneal injections. Probiotics were added to the double therapy two weeks before the sacrifice. Assessment was performed by clinical observation, histological analysis. Reactive oxigen species (ROS) activities and molecular analysis of Interleukin 3 and 6. Tumor Necrosis Factor alpha. AMP-activated protein Kinase and the mammalian target of rapamycin. decreases in the level of tumorigenesis resulted, to various extents, with the different treatment regimens.The combination of rapamycin and metformin had no significant result, however, after adding probiotics to the combination, there was a marked delay in tumor formation and reduction of its siza, suppression of ROS and decrease in inflammatory cytokines as well as an inhibition of phospohorylated mTOR. Existing evidence clearly supports the use of rapamycin and metformin especially in the presence of probiotics. It also highlighted the possible mechanism of action of the 2 drugs through AMPK and mTOR signaling pathways and offered preliminary data on the significant role of probiotics in the combination. Further investigation to clarify is needed.",
author = "Manfredi Rizzo and Francesco Cappello and Angelo Leone and Giovanni Tomasello and Assaad Eid and Geagea, {Alice Gerges} and Kattar, {Sahar Al} and C{\'e}line Gracia and Liliane Massaad-Massade and Abdo Jurjus",
year = "2019",
language = "English",
volume = "10",
pages = "1284--1305",
journal = "Default journal",

}

TY - JOUR

T1 - A NOVEL THERAPEUTIC APPROACH TO COLORECTAL CANCER IN DIABETES: ROLE OF METFORMIN AND RAPAMYCIN

AU - Rizzo, Manfredi

AU - Cappello, Francesco

AU - Leone, Angelo

AU - Tomasello, Giovanni

AU - Eid, Assaad

AU - Geagea, Alice Gerges

AU - Kattar, Sahar Al

AU - Gracia, Céline

AU - Massaad-Massade, Liliane

AU - Jurjus, Abdo

PY - 2019

Y1 - 2019

N2 - The link between colorectal cancer (CRC), diabetes mellitus (DM) and inflammation is well established, and polyterapy, including rapamycin, has been adopted. This study is a novel approach that aimed at assessing the effect of a combination therapy of metformin and rapamycin on the control or prevention of CRC in diabetic animals, in presence or absence of probiotics. Fifty NOD/SCIDs male mice developed xenograft by inoculating HCT16 cells. They were equally divided into diabetics (induced by Streptozocin) and non-diabetics. Metformin was given in drinking water, whereas rapamycin was administered via intra-peritoneal injections. Probiotics were added to the double therapy two weeks before the sacrifice. Assessment was performed by clinical observation, histological analysis. Reactive oxigen species (ROS) activities and molecular analysis of Interleukin 3 and 6. Tumor Necrosis Factor alpha. AMP-activated protein Kinase and the mammalian target of rapamycin. decreases in the level of tumorigenesis resulted, to various extents, with the different treatment regimens.The combination of rapamycin and metformin had no significant result, however, after adding probiotics to the combination, there was a marked delay in tumor formation and reduction of its siza, suppression of ROS and decrease in inflammatory cytokines as well as an inhibition of phospohorylated mTOR. Existing evidence clearly supports the use of rapamycin and metformin especially in the presence of probiotics. It also highlighted the possible mechanism of action of the 2 drugs through AMPK and mTOR signaling pathways and offered preliminary data on the significant role of probiotics in the combination. Further investigation to clarify is needed.

AB - The link between colorectal cancer (CRC), diabetes mellitus (DM) and inflammation is well established, and polyterapy, including rapamycin, has been adopted. This study is a novel approach that aimed at assessing the effect of a combination therapy of metformin and rapamycin on the control or prevention of CRC in diabetic animals, in presence or absence of probiotics. Fifty NOD/SCIDs male mice developed xenograft by inoculating HCT16 cells. They were equally divided into diabetics (induced by Streptozocin) and non-diabetics. Metformin was given in drinking water, whereas rapamycin was administered via intra-peritoneal injections. Probiotics were added to the double therapy two weeks before the sacrifice. Assessment was performed by clinical observation, histological analysis. Reactive oxigen species (ROS) activities and molecular analysis of Interleukin 3 and 6. Tumor Necrosis Factor alpha. AMP-activated protein Kinase and the mammalian target of rapamycin. decreases in the level of tumorigenesis resulted, to various extents, with the different treatment regimens.The combination of rapamycin and metformin had no significant result, however, after adding probiotics to the combination, there was a marked delay in tumor formation and reduction of its siza, suppression of ROS and decrease in inflammatory cytokines as well as an inhibition of phospohorylated mTOR. Existing evidence clearly supports the use of rapamycin and metformin especially in the presence of probiotics. It also highlighted the possible mechanism of action of the 2 drugs through AMPK and mTOR signaling pathways and offered preliminary data on the significant role of probiotics in the combination. Further investigation to clarify is needed.

UR - http://hdl.handle.net/10447/345175

M3 - Article

VL - 10

SP - 1284

EP - 1305

JO - Default journal

JF - Default journal

ER -